These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 21436692)
1. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance. Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692 [TBL] [Abstract][Full Text] [Related]
2. [Reversing paclitaxel-resistance of SKOV3-TR30 cell line by curcumin]. Qiu J; Fu YF; Cheng Q; Cheng XD; Xie X; Lü WG Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(27):1926-8. PubMed ID: 23134969 [TBL] [Abstract][Full Text] [Related]
3. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259 [TBL] [Abstract][Full Text] [Related]
4. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258 [TBL] [Abstract][Full Text] [Related]
5. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling. Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607 [TBL] [Abstract][Full Text] [Related]
6. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells. Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572 [TBL] [Abstract][Full Text] [Related]
7. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD]. Cheng G; Tian F; Li Y Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816 [TBL] [Abstract][Full Text] [Related]
8. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells. Shuang T; Wang M; Shi C; Zhou Y; Wang D FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. Li M; Yin J; Mao N; Pan L Oncol Rep; 2013 Jan; 29(1):58-66. PubMed ID: 23064469 [TBL] [Abstract][Full Text] [Related]
10. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells. Tong L; Chen W; Wu J; Li H Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314 [TBL] [Abstract][Full Text] [Related]
11. [Preliminary study of the prohibitin protein and paclitaxel resistance in ovarian cancer]. Tang J; Cao L; Yi H; Tang C Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1221-7. PubMed ID: 23281375 [TBL] [Abstract][Full Text] [Related]
12. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254 [TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Kumar A; Soprano DR; Parekh HK Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393 [TBL] [Abstract][Full Text] [Related]
14. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line. Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419 [TBL] [Abstract][Full Text] [Related]
15. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells. Sun NK; Huang SL; Chang TC; Chao CC J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725 [TBL] [Abstract][Full Text] [Related]
16. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides. Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384 [TBL] [Abstract][Full Text] [Related]
17. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910). Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842 [TBL] [Abstract][Full Text] [Related]
18. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Lamendola DE; Duan Z; Yusuf RZ; Seiden MV Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840 [TBL] [Abstract][Full Text] [Related]
19. [Glycogen synthase kinase-3beta (GSK-3beta) promotes proliferation of ovarian cancer cells in vitro]. Cao Q; Feng YJ Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):804-9. PubMed ID: 17415999 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of UTP23 promotes paclitaxel resistance and predicts poorer prognosis in ovarian cancer. Fu Z; Wang C; Chen Y; Zhang X; Wang X; Xie X Pathol Res Pract; 2019 Nov; 215(11):152625. PubMed ID: 31540773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]